Thursday, February 26 at 15:00 GMT | 16:00 CET | 10:00 EST | 07:00 PST
Cardiac assays should not be short-term. Yet most discovery and safety teams still build multi-year programs on short-lived cardiomyocyte batches. That creates variability, repeated revalidations, and rising costs per program, driven by delays and increased decision risk as discovery and safety pipelines advance.
This webinar aims to introduce a different model.
Ncyte vCardiomyocytes are manufactured as a single multi-billion-cell batch that supports three to five years of consistent assay performance. Data remain stable across MEA, impedance, and calcium imaging, while requiring around forty percent fewer cells per well. The result? Predictable data, fewer reruns, and a materially lower operational and economic burden across long discovery and safety.
We will walk you through the scientific rationale, show real performance data, and quantify the economic impact using a live cost model supported with internal benchmarks
Key learning objectives
- Why batch-to-batch variability undermines long discovery and safety programs
- How multi-year cardiomyocyte continuity improves data confidence across modalities
- What using fewer cells per well actually means for throughput and assay robustness
- How eliminating most revalidations translates into measurable cost savings
- When stable supply becomes a strategic advantage rather than a procurement issue
Who should attend?
If you are running cardiac assays at scale and planning beyond the next quarter, this session will give you a clearer scientific and economic framework for decision-making. Join the webinar to review the data, explore the cost scenarios, and assess whether a multi-year cardiomyocyte platform fits your program.
Fill out the form below to register!
Speakers
Mariana holds a PhD in molecular biology from the University of SanMartin (Buenos Aires) and has worked at several universities in the US for more than eight years, specializing in stem cell biology. Throughout her experience in academic research, she gained distinct knowledge and expertise in both disease modeling and biobank building, and in the differentiation of iPSCs into cardiac and neuronal cell types. In 2022, Mariana joined the manufacturing team at Ncardia, where she pursues new iPSC manufacturing procedures and scale-up processes to support their application in regenerative medicine and drug discovery.
.png)